Apogee Therapeutics Inc (APGE)

Currency in USD
89.28
+0.81(+0.92%)
Closed·
89.320.00(0.00%)
·
Trading near 52-week High
APGE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
86.0789.69
52 wk Range
31.6089.69
Key Statistics
Prev. Close
88.47
Open
88.47
Day's Range
86.07-89.69
52 wk Range
31.6-89.63
Volume
690.92K
Average Vol. (3m)
1.03M
1-Year Change
178.6517%
Book Value / Share
13.39
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
APGE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
116.87
Upside
+30.90%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings downwards for the upcoming period

Apogee Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Compare APGE to Peers and Sector

Metrics to compare
APGE
Peers
Sector
Relationship
P/E Ratio
−25.8x−93.8x−0.5x
PEG Ratio
0.92−1.170.00
Price / Book
7.3x11.2x2.6x
Price / LTM Sales
-10.2x3.2x
Upside (Analyst Target)
32.2%41.5%47.6%
Fair Value Upside
Unlock−15.5%6.1%Unlock

Analyst Ratings

14 Buy
3 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 116.87
(+30.90% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BTIG
Buy137.00+53.45%-MaintainMar 30, 2026
Mizuho
Buy110.00+23.21%105.00MaintainMar 30, 2026
Guggenheim
Buy160.00+79.21%130.00MaintainMar 24, 2026
Citi
Buy125.00+40.01%95.00MaintainMar 24, 2026
Canaccord
Buy130.00+45.61%89.00MaintainMar 23, 2026

Earnings

Latest Release
Mar 02, 2026
EPS / Forecast
-1.03 / -0.62
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

APGE Income Statement

People Also Watch

142.520
AAOI
-2.64%
34.410
PL
+1.41%
21.73
SRPT
-1.90%
55.74
WHR
+0.85%
824.01
LITE
-3.37%

FAQ

What Is the Apogee Therapeutics (APGE) Stock Price Today?

The Apogee Therapeutics stock price today is 89.28 USD.

What Stock Exchange Does Apogee Therapeutics Trade On?

Apogee Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Apogee Therapeutics?

The stock symbol for Apogee Therapeutics is "APGE."

What Is the Apogee Therapeutics Market Cap?

As of today, Apogee Therapeutics market cap is 6.53B USD.

What Is Apogee Therapeutics's Earnings Per Share (TTM)?

The Apogee Therapeutics EPS (TTM) is -4.22.

When Is the Next Apogee Therapeutics Earnings Date?

Apogee Therapeutics will release its next earnings report on May 18, 2026.

From a Technical Analysis Perspective, Is APGE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Apogee Therapeutics Stock Split?

Apogee Therapeutics has split 0 times.

How Many Employees Does Apogee Therapeutics Have?

Apogee Therapeutics has 261 employees.

What is the current trading status of Apogee Therapeutics (APGE)?

As of Apr 16, 2026, Apogee Therapeutics (APGE) is trading at a price of 89.28 USD, with a previous close of 88.47 USD. The stock has fluctuated within a day range of 86.07 USD to 89.69 USD, while its 52-week range spans from 31.60 USD to 89.63 USD.

What Is Apogee Therapeutics (APGE) Price Target According to Analysts?

The average 12-month price target for Apogee Therapeutics is 116.87 USD, with a high estimate of 160 USD and a low estimate of 82 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +30.90% Upside potential.

What Is the APGE Premarket Price?

APGE's last pre-market stock price is 88.01 USD. The pre-market share volume is 800.00, and the stock has decreased by -0.46, or -0.52%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.